Front-line Treatment of Philadelphia Positive (Ph+)/BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) With AP24534 (Ponatinib), a New Potent Tyrosine Kinase Inhibitor (TKI).

Trial Profile

Front-line Treatment of Philadelphia Positive (Ph+)/BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) With AP24534 (Ponatinib), a New Potent Tyrosine Kinase Inhibitor (TKI).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 31 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top